Policy & Regulation
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
3 July 2025 - Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), an Australian clinical-stage biotech company, announced on Wednesday that it has executed an exclusive global license agreement with...
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
3 July 2025 - Ascletis Pharma Inc. (HKEX: 1672), a China-based pharmaceutical company, announced on Wednesday that the first participants with obesity or overweight with at least one weight-related co...
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval
3 July 2025 - Jacobio Pharma (1167.HK), a China-based pharmaceutical company, announced on Wednesday that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibit...
RedHill Biopharma recruiting for expanded Phase 2 opaganib/darolutamide combination study in advanced prostate cancer
2 July 2025 - RedHill Biopharma Ltd (NASDAQ: RDHL), an Israeli specialty biopharmaceutical company, announced on Tuesday the initiation of patient recruitment into the Phase 2 study evaluating the eff...
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly
1 July 2025 -

Sweden-based biopharmaceutical company Camurus AB (NASDAQ STO: CAMX) announced on Tuesday that it has received marketing authorisati...

Genenta Science reports long-term survival signals in glioblastoma study as genitourinary trial advances
1 July 2025 -

Clinical stage immuno-oncology company Genenta Science SPA (NASDAQ: GNTA) on Tuesday announced long-term follow-up data from its gl...